

We got the manufacturing license!

We entered the first quarter of 2023 with fair wind in our sails, and it is my firm belief that we can now continue the positive momentum that we saw in 2022. Shortly before the new year, we could really kick off the work around XNK03 with the aim to eventually bring more effective treatment to patients with locally advanced or metastatic urothelial cancer. We have advanced this program further during this quarter. Going forward our focus is on advancing the XNK project pipeline and to benefit from the rising interest in natural killer (NK) cell therapies to treat cancer. We now have pre-clinical and clinical programs and programs spanning both hematological malignancies and solid tumors.

In March, we received a manufacturing license from the Swedish Medical Products Agency, which means that we can now start producing at scale for our planned clinical studies. Our new Good Manufacturing Practice (GMP) clean room facility, at XNK's premises in the Novum Research Park and co-located with the Karolinska University Hospital, was completed in September 2022. The now approved GMP facility will enable the aseptic production of Advanced Therapy Medicinal Products (ATMPs) and clinical material for future studies and make possible larger clinical studies with our NK cell-based therapies. We are very happy and proud to have received this license. It is an important milestone for XNK, and we are now well positioned for significant value creation with three to four potential phase I/II readouts over the coming 3 years. This ambitious pipeline and manufacturing strategy fits very well with our licensing focus for each program.

During the first quarter, we also noticed that our programs continued to attract interest in the scientific community and among investors. In February, we were invited to present at Redeye's Regenerative Medicine/Cell Therapy event in Stockholm, and at the end of March we participated with a strong team at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA. We are very excited to have been invited to participate in this prestigious conference with two podium presentations and a panel discussion. This underlines XNK's position at the forefront of NK cell therapy development today, which was further manifested in an article in Nature Biotechnology in February reviewing the field.

As our programs draw an increasing interest from the scientific community, we continue to attract talented people. In January, we announced that Dr. Peter Hovstadius had joined us as Chief Medical Officer (CMO) and member of the company's management team. Peter has a solid background in oncology and clinical trials development from both academia and the pharma industry. He will be a key player on the XNK team as we continue to successfully develop and expand our project pipeline. I would also like to thank Dr. Johan Aschan for his contribution to XNK and wish him luck in his retirement. I'm grateful that he will continue to support the company in the role of Senior Medical Advisor. XNK Therapeutics AB
info@xnktherapeutics.com Hälsovägen 7, Novum xnktherapeutics.com SE-141 57 Huddinge



With a solid financial position and positive development in our projects, as well as the completion of the GMP clean room facility and other recent important events, I look forward to updating you on upcoming milestones. In the meantime, I would like to remind you of the opportunity to sign up for our press releases via our website. And if you also follow XNK on LinkedIn, you will get a few updates every weeks as to what is happening in the company.

Johan Liwing